menu
    • menu

    Company profile for GRI Bio

    NEW Drugs in Dev: 3
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    GRI Bio is a clinical stage biotech company focused on fundamentally changing the way inflammatory disease is treated by targeting NKT immune cells earlier in the inflammatory chain to interrupt disease progression more effectively. GRI Bio’s lead program, GRI-0621, is a small molecule RAR-βɣ dual agonist that inhibits the activity of human Type 1 invariant NKT (iNKT) cells, returning the immune system to homeostasis. Oral...
    GRI Bio is a clinical stage biotech company focused on fundamentally changing the way inflammatory disease is treated by targeting NKT immune cells earlier in the inflammatory chain to interrupt disease progression more effectively. GRI Bio’s lead program, GRI-0621, is a small molecule RAR-βɣ dual agonist that inhibits the activity of human Type 1 invariant NKT (iNKT) cells, returning the immune system to homeostasis. Oral dosing of GRI-0621 has been shown to inhibit iNKT cells in patients and improve fibrosis in multiple disease models.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    GRI BioUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2223 Avenida De La Playa Ste 208, La Jolla, California, 92037
    Telephone
    Telephone
    (619) 400-1171
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.gribio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    SCOPE Summit

    SCOPE Summit

    Not Confirmed

    envelop Contact Supplier

    SCOPE Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    GRI Bio Shows Promising Phase 2A Data For IPF Lung Repair
    GRI Bio Shows Promising Phase 2A Data For IPF Lung Repair

    28 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/28/3227630/0/en/GRI-Bio-Delivers-Compelling-New-Phase-2a-Gene-Expression-Data-Demonstrating-Improvements-in-Key-Drivers-of-Fibrosis-and-Lung-Repair-in-IPF.html

    GLOBENEWSWIRE
    28 Jan 2026
    Share Share
    GRI Bio Secures New U.S. Patent For Novel Compound Structures
    GRI Bio Secures New U.S. Patent For Novel Compound Structures

    26 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/26/3225639/0/en/GRI-Bio-Secures-New-U-S-Composition-of-Matter-Patent-Covering-Novel-Compound-Structures.html

    GLOBENEWSWIRE
    26 Jan 2026
    Share Share
    GRI Bio Announces Reverse Stock Split
    GRI Bio Announces Reverse Stock Split

    21 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/21/3223219/0/en/GRI-Bio-Announces-Reverse-Stock-Split.html

    GLOBENEWSWIRE
    21 Jan 2026
    Share Share
    GRI Bio Reports Positive Phase 2a Data in IPF for GRI-0621
    GRI Bio Reports Positive Phase 2a Data in IPF for GRI-0621

    08 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/08/3215315/0/en/GRI-Bio-Announces-Additional-Positive-Data-from-Phase-2a-Study-in-Idiopathic-Pulmonary-Fibrosis-Strengthening-Clinical-Proof-of-Concept-for-GRI-0621.html

    GLOBENEWSWIRE
    08 Jan 2026
    Share Share
    GRI Bio Announces Closing Of $8.0 Million Public Offering
    GRI Bio Announces Closing Of $8.0 Million Public Offering

    12 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/12/3204858/0/en/GRI-Bio-Announces-Closing-of-8-0-Million-Public-Offering.html

    GLOBENEWSWIRE
    12 Dec 2025
    Share Share
    GRI Bio Announces Pricing Of $8,000,000 Million Public Offering
    GRI Bio Announces Pricing Of $8,000,000 Million Public Offering

    11 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/11/3204000/0/en/GRI-Bio-Announces-Pricing-of-8-000-000-Million-Public-Offering.html

    GLOBENEWSWIRE
    11 Dec 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search